Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND METHODS: Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7–6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years. RESULTS: HbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c <5.7%). In the untreated group, 40.2% progressed to T2D (HbA1c >6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males’ Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005). CONCLUSIONS: Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There appears to be a higher likelihood for undiagnosed hyperglycemia in those seeking fertility.1557”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1557]
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Guerrero-Romero, F., Simental-Mendía, L. E., González-Ortiz, M., Martínez-Abundis, E., Ramos-Zavala, M. G., Hernández-González, S. O., Jacques-Camarena, O., & Rodríguez-Morán, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0288 · Cited by 2,247
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 2×
“above which further weight loss may not result in additional preventive benefits (11).”
BackgroundSelf-citationSex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · cited 2×
“Clinical trials assessing efficacy of lifestyle interventions as well as pharmacotherapy for obesity are characterized by high attrition rates (22).”
BackgroundEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30097-9 · Cited by 816 · cited 1×
“In 2017, therewere 451million people (ages 18–99 years) with diabetes worldwide, and 5million deaths were attributable to diabetes (39).”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“is likely improvement in insulin sensitivity (29,30).”
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Research works printed but not linked: 1
- Saad, 2017, Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years, Diabetes, 66, A305
Cited by
Items 101–164 of 164
Morbidity and mortality in men: Role of androgens
Fallara, G., Pozzi, E., Corsini, C., Belladelli, F., Boeri, L., Capogrosso, P., Montorsi, F., & Salonia, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101662 · Cited by 5
Male Hypogonadism (According to the Materials of the European Association of Urology)
Gorpynchenko, I., Gurzhenko, Y., & Spyrydonenko, V. (2022) · Health of Man · doi:10.30841/2307-5090.4.2022.274432 · Cited by 3
“Терапія тестостероном покращує резистентність до інсуліну та гіперглікемію, знижує рівень холестерину та холестерину ЛПНЩ [14–18], а при гіпогонадальному ЦД2 покращує глікемічний контроль [15, 19, 20].”
Vásquez-Tirado, G. A., Guarniz-Salavarria, J. D., Quispe-Castañeda, C. V., Contreras-Cabrera, J. M., Cuadra-Campos, M. D. C., Meregildo-Rodríguez, E. D., Segura-Plasencia, N. M., & Arbayza-Ávalos, Y. K. (2024) · Endocrine · doi:10.1007/s12020-024-04019-4 · Cited by 4
“Some studies already support those above in their results, such as the results of Yassin et al. [54] and Wittert et al. [55], the latter in an RCT in Australia showing that testosterone can prevent or reverse T2DM in adult obese patients who have low testosterone levels.”
Zhao, X., Sakamoto, S., Yamada, Y., Sato, K., Tamura, T., Shibata, H., Sazuka, T., Imamura, Y., & Ichikawa, T. (2025) · International Journal of Urology · doi:10.1111/iju.70125 · Cited by 3
“treatment for TD and has been shown to alleviate or reverse these symptoms [40, 41].”
Hormonal regulation in diabetes: Special emphasis on sex hormones and metabolic traits
Ravi, H., Das, S., Rajeswari, V. D., Venkatraman, G., Choudhury, A. A., Chakraborty, S., & Ramanathan, G. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.015 · Cited by 3
Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
Ferreira, M., & Mendonça, J. A. (2022) · Drugs in Context · doi:10.7573/dic.2021-8-12 · Cited by 3
Pelusi, C., Bartolomeo, N., Lisco, G., Baccini, M., Fanelli, F., Pergola, G. D., Triggiani, V., Pagotto, U., & Giagulli, V. A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220304110958 · Cited by 7
Hypogonadotropic Hypogonadism in Diabesity: Pathogenic Factors and Therapeutic Implications
Dandona, P., Dhindsa, S., & Ghanim, H. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0019 · Cited by 4
“of normality, and to reverse diabetes in 33% of patients with diabetes and HH for an 8-year period.(9,10) In addition to the mentioned effects, testosterone also increased the expression of the androgen recep-”
BackgroundNieschlag, E., & Behre, H. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_36 · Cited by 2
Lin, Y., Zou, J., Hong, M., Huang, X., & Wu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1580036 · Cited by 2
Effects of testosterone deficiency and therapy on the cardiometabolic syndrome in men
Saad, F., & Traish, A. M. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.08.004 · Cited by 2
Self-citationDefeudis, G., Maddaloni, E., Rossini, G., Tommaso, A. D. D., Mazzilli, R., Palma, P. D., Pozzilli, P., & Napoli, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185333 · Cited by 3
“have observed that TRT, with testosterone undecanoate injections for 8–11 years, prevents the progression of DM in patients with T2DM, even restoring the euglycemic state [24].”
BackgroundImproving the annual monitoring rates of testosterone replacement therapy patients in primary care
Hassoun, O., Starostka, M., Shearer, H. M., Millar, A., Hassoun, S. A., & Isles, C. (2022) · BMJ Open Quality · doi:10.1136/bmjoq-2021-001784 · Cited by 3
Xuan, X., Hamaguchi, M., Cao, Q., Takuro, O., Hashimoto, Y., Obora, A., Kojima, T., Fukui, M., Yuan, G., Guo, Z., et al. (2020) · doi:10.21203/rs.3.rs-42381/v1 · Cited by 3
“The exposure in our study was the TyG index which was calculated based on the following formula: TyG = ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/ 2)] [24, 25].”
MethodImpact of testosterone levels and testosterone replacement ther-apy on men’s health
Karbowska, Z., Cierpiszewska, K., Maruszczak, K., Sukhachova, I., Szwankowska, D., & Piotrowski, I. (2023) · Journal of Medical Science · doi:10.20883/medical.e856 · Cited by 1
Armeni, E. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.40 · Cited by 3
Nikolaou, E., Tziastoudi, M., Gougoura, S. G., Filippidis, G., Dousdampanis, P., Bargiota, Α., Mertens, P. R., Eleftheriadis, T., Hadjigeorgiou, G. M., Koukoulis, G. N., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01406-9 · Cited by 3
“Low serum testosterone in men has been associated with the metabolic syndrome, diabetes mellitus and insulin resistance [8–10].”
BackgroundImpact of Testosterone Deficiency and Testosterone Therapy on Men’s Health
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_13 · Cited by 1
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
Abu-Moch, M., Azab, A. N., Yousef, M., & Agam, G. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119356 · Cited by 1
Male Sexual Health and Cardiovascular Disease
Greear, G., Garg, N., & Hsieh, T. (2020) · Current Sexual Health Reports · doi:10.1007/s11930-020-00281-5 · Cited by 1
Methandienone contributes directly on develop central serous chorioretinopathy in athletes
Algon, A. A. A., Almulla, A. F., & Naser, A. F. (2022) · AIP conference proceedings · doi:10.1063/5.0067410 · Cited by 1
Yassin, A. A. (2022) · Current Trends in Internal Medicine · doi:10.29011/2638-003x.100061 · Cited by 1
“Support for this comes from other long-term real-world evidence studies showing that despite increases in hematocrit, there was no increased risk for venous thromboembolism, myocardial infarction, stroke, or mortality [2,19].”
ResultSelf-citationNieschlag, E., & Behre, H. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_36 · Cited by 1
В.В., С., Шаповалова, А. Б., Мочалов, П. А., Канавец, Н. С., Азыдова, Г. В., Е.Б., К., & Федосеева, В. В. (2024) · International journal of medicine and psychology. · doi:10.58224/2658-3313-2024-7-5-18-26 · Cited by 1
Effects of Hypogonadism and Testosterone Therapy on Diabetic Foot Complications
Jupiter, D. C., Faaitiiti, K. L., Rodriguez, R. A., Polychronopoulou, E., & López, D. S. (2024) · Journal of the American Podiatric Medical Association · doi:10.7547/22-112 · Cited by 2
Age-Related Testosterone Deficiency Merits Treatment
Traish, A. M. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0019 · Cited by 4
Male hypogonadism and pre-diabetes interplay: association or causal interaction? A systematic review
Greco, C., Corleto, R., Ebert, R., Simoni, M., Rochira, V., & Santi, D. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.14 · Cited by 1
Connecting Obesity and Reproductive Disorders
Ahima, R. S., & Dias, J. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_54 · Cited by 3
Antonič, K. G. (2020) · Slovenian Medical Journal · doi:10.6016/zdravvestn.2921
George, M., Yulia, T., Anas, A., & Svetlana, K. (2020) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000043
“Recent study showed that long-term TTh may prevent prediabetes progression to T2D in men with hypogonadism, improve glycemic and lipid metabolism [22].”
BackgroundZum Beitrag: „Testosteronmangel im Alter – was ist zu tun“
Markolf Hanefeld, E., Zitzmann, M., & Nieschlag, E. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1398-8242
Saad, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-61417-4_9
Self-citationNashawi, M., Ahmed, M. S., Ahmad, M. I., Issa, O., & Abualfoul, M. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1139
“Nevertheless, there is conflicting evidence for this mechanism, as it has been replicated in supraphysiologic testosterone environments, and there are mixed results of testosterone and lipid distribution in the hypogonadal population, such as those with sarcopenic obesity [19-24].”
BackgroundDhindsa, S. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch85
Jalal, M. J. A., & John, S. (2022) · Eastern Journal of Medical Sciences · doi:10.32677/ejms.v7i1.3364
“Low testosterone can be prevented in diabetes patients by focusing on their lifestyle [16].”
BackgroundBrèves: Effets métaboliques de la substitution en androgènes chez l’homme
(2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30101-4
Xu, W., Qadir, F., Nasteska, D., de Sa, P. M., Gorvin, C. M., Blandino-Rosano, M., Evans, C. R., Ashford, F. B., Bitsi, S., Fan, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4114953
Nieschlag, E., & Behre, H. M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_36-1
Yassin, A. A., Albaba, B., Talib, R., Aboumarzouk, O., Alwani, M., & Arous, M. M. (2022) · Current Trends in Internal Medicine · doi:10.29011/2638-003x.100063 · Cited by 2
“This makes testosterone therapy a particularly promising treatment, as it can reduce both fatty liver 4 and prevent and possibly reverse type 2 diabetes [33-35].”
BackgroundSelf-citationDawood, A. A., Husain, W. N., & Al-Samarrai, R. R. H. (2022) · AIP conference proceedings · doi:10.1063/5.0122156
Imani, R., Norooziseyedhosseini, H., Sumra, B., Napit, S., Shrestha, R., & Patel, T. D. (2023) · doi:10.22541/au.167655903.38556293/v1
Roshandel, D., Paterson, A. D., & Dash, S. (2023) · medRxiv · doi:10.1101/2023.03.09.23287061
Genderaspekte in der Behandlung von Diabetes mellitus
Gisinger, T. (2023) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-023-00193-4
“Aber auch bei Männern gibt es Berichte, dass bei Testosteronmangel eine Substitutionstherapie einen positiven Einfluss auf die Weiterentwicklung von Prädiabetes zu Diabetes mellitus hat [7].”
BackgroundFunctional Hypogonadism: Diabetes Mellitus, Obesity, Metabolic Syndrome, and Testosterone
Meirelles, R. M. D. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_8
Testosterone Level and Risk of Diabetes: Follow-Up Study
Rezanezhad, B., Borgquist, R., & Elzanaty, S. (2023) · Medical Research Archives · doi:10.18103/mra.v11i9.4473
Connecting Obesity and Reproductive Disorders
Ahima, R. S., & Dias, J. P. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_54-1
Connecting Obesity and Reproductive Disorders
Ahima, R. S., & Dias, J. P. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_54-2
Testosteronbehandlung: kein positiver Effekt auf den Progress eines Prädiabetes
Heinitz, S. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01195-9
Moldovan, R. A., Hidalgo, M. R., Castañé, H., Jiménez-Franco, A., Joven, J., Burks, D. J., Galán, A., & Garcia‐García, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613678
“…relate to genetic sex - the prenatal testosterone programming effect in males and the activating role of sex hormones during puberty [37, 40–42] - contribute to sexual biases in body fat distribution [43, 44], body mass index, and obesity [45, 46], and in T2D prevalence [47],…”
BackgroundDeischinger, C., Harreiter, J., & Kautzky‐Willer, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65952-2_6
Funktioneller Hypogonadismus: Diabetes mellitus, Adipositas, metabolisches Syndrom und Testosteron
Meirelles, R. M. D. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_8
Dissecting genetic regulation of metabolic coordination
Hector, E. C., Zhang, D., Tian, L., Feng, J., Yin, X., Xu, T., Laakso, M., Bai, Y., Xiao, J., Kang, J., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf095 · Cited by 1
Fortingo, N., Sandhu, M., Greear, G., Hsieh, T., Horns, J. J., Das, R., Hotaling, J., & Santiago‐Lastra, Y. (2025) · Frontiers in Urology · doi:10.3389/fruro.2025.1500839
“Men with SB who exhibit symptomatic hypogonadism may bene fi t from TST, which may also improve metabolic parameters (16 – 18).”
Hypogonadism in Men with Obesity and Type 2 Diabetes
Dhindsa, S., Ghanim, H., & Dandona, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_18
Testosterone Therapy and Prevention of Type 2 Diabetes in Men with Hypogonadism
Wittert, G. A., & Mauvais‐Jarvis, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_19
Long-Term Effects of Testosterone Therapy in Men with Testosterone Deficiency
Saad, F., & Caliber, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_17
Self-citationAndrogènes et diabète de type 2
Chevalier, N., & Magnifico, S. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.07.004
Gadallah, A. I., Abdelhaffez, A., Hussein, O. A., Sayed, S. A., Abdelhakiem, M. A. H., & El-Mottaleb, N. A. A. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0063
He, Q., Xu, Y.-Y., Tan, X., & Yin, Y. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02321-y
“Functional hypogonadism is clinically intertwined with obesity, insulin resistance, and T2DM, and observational studies have examined diabetes-related outcomes in hypogonadal men receiving testosterone therapy [56–59].”
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1 · Cited by 1
Karczewska, K., Ziółek, M. A., Domagała, K., Maroszek, M., Szymczak, K., Janik, B., Bakier, A., Kuniewicz, J., Tokarczyk, M., Kuczkowska, J. M., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5457
Hashimi, M. A., Ho, C. C. K., & Kadıoğlu, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-29112-7_16
Metadata
- Authors
- Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T.
- Affiliations
- Dresden International University (DE)
- Private Urology Practice, Bremerhaven, Germany
- American Medical Writers Association (US)
- Boston University (US)
- Gulf Medical University (AE)
- University of Alabama at Birmingham (US)
- Corresponding author
- Saad, Farid
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-03-12
- Volume
- 42
- Issue
- 6
- Pages
- 1104-1111
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2922405541
- Cited by
- 164
- References
- 45
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 20 · 2023: 26 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 11
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer AG
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- testosterone replacement therapy, hypogonadism, prediabetes, type 2 diabetes prevention, testosterone undecanoate, glycemic control, HbA1c, lipid profile, aging male symptoms, myocardial infarction, mortality, men
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypogonadism, Male, Middle Aged, Prediabetic State, Registries, Testosterone, Triglycerides, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.